Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Cleared to Begin Second Phase I Trial of siRNA Cancer Drug

Premium

Tekmira Pharmaceuticals this week announced that it has received approval from the US Food and Drug Administration to go forward with a new phase I study of its siRNA-based cancer drug TKM-PLK1 in collaboration with the National Cancer Institute.

Tekmira moved the drug, which targets polo-like kinase 1, into phase I testing early this year (GSN 1/6/2011). The company said that the new study, which will be conducted in parallel with the ongoing trial, will provide an “early opportunity to validate the drug's mechanism of action.”

"Patients in this new study, who will have either primary liver cancer or liver metastases, will receive TKM-PLK1 delivered directly into the liver via hepatic artery infusion,” Tekmira Preisdent and CEO Mark Murray said in a statement. “The trial design will allow us to measure tumor delivery, polo-like kinase 1 messenger RNA knockdown, and RNA interference activity in tumor biopsies from all of the patients treated.”

Interim phase I data on TKM-PLK1 is expected before year end.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.